YC W17
Indee Labs
Enabling T cell immunotherapy discovery, development and manufacturing
About
Intracellular delivery is the most problematic step in T cell immunotherapy discovery, development and manufacturing. Indee Labs is developing a non-viral intracellular delivery system based on microfluidic vortex shedding (µVS) to rapidly deliver nucleic acids, proteins and gene editing complexes to patient and donor T cells with minimal perturbation.
Founder
Family Office Investors
2 deals trackedAltss has tracked family office activity in Indee Labs. Investors shown are from our private markets database.
- Aaron Vandevender (Angel)
- The Quantitative Foundation
Industry & Focus
HealthcareDrug Discovery and DeliveryGene TherapyMicrofluidicsCell Therapy